Medigene announces formation of new Scientific Advisory Board
Medigene AG announced the appointment of eight leading experts to its new immuno-oncology-focused Scientific Advisory Board (SAB). The SAB will consult the company with regard to strategic options and future perspectives within its research and development activities. The SAB will thereby further strengthen Medigene's leadership position in the development of innovative cancer immunotherapies.
The inaugural members of Medigene's new Scientific Advisory Board are:
The Chairman, Prof. Dr. Ernst-Ludwig Winnacker, and the following members:
- Dr. Micha Drukker
Leader of the research group "Human Pluripotent Stem Cell Lineage Choice" and head of the core facility "Human Induced Pluripotent Stem Cells" at the Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Munich/Neuherberg, Germany
Group Leader at the Research Unit Gene Vectors, Haematologikum, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Munich, Germany
Head of the Division of Immunogenetics in the Tumor Immunology Program at the German Cancer Research Center (DKFZ) and member of the Board of Directors of the National Center for Tumor Diseases (NCT) in Heidelberg, Germany
Former CEO of Kiadis Pharma, international experienced life science industry expert, held various executive positions in different companies during last two decades
Senior Investigator, CCR Deputy Director, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
Professor of Immunology within Medicine at the University of Southampton, UK
Professor of Immunology within the Department of Tumor Immunology at the Nijmegen Centre for Molecular Life Sciences, The Netherlands
"It is a great pleasure to announce the formation of our excellent new Scientific Advisory Board at Medigene," said Prof. Dolores Schendel, Chief Executive Officer and Chief Scientific Officer of Medigene AG. "The diverse expertise in immunology, gene therapy, cancer and stem cell research present in this board will support our ongoing and future development activities in cancer immunotherapies. We aim to tap the profound knowledge of these individuals and their vast networks to challenge, support and advise Medigene."
Other news from the department business & finance
